A Phase 2 interventional study of Dobutamine and TnECHO in Hypoxic-ischemic Encephalopathy (HIE), sponsored by University of Alberta. Recruiting at 2 sites in Canada. Open to participants aged 1 Day to 1 Day. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of Alberta · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hypoxia-Ischemia, Brain with a site in Canada — 10 open to participants now, 10 under way, none of them phase 3. Hypoxia-Ischemia, Brain · Canada.
Among the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 2, and was the 17th registered.
261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.
Browse Hypoxia-Ischemia, Brain studies →10 of the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
University of Calgary · Sites in Canada
Pia Wintermark · Sites in Canada, United States
Ages 0 min–48 hrs
Hamilton Health Sciences Corporation · Sites in Canada
Ages 1 days–15 days
University of Michigan · Sites in Canada, United States, Australia and 2 more countries
Ages 2 days–17 yrs
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.
This study: 1 Day to 1 Day · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 50 across 156 interventional studies indexed under Hypoxia-Ischemia, Brain.
Median enrollment 42 across the 14 interventional studies, 50 across the 5 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 19 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
University of Alberta has 1 study filed under Hypoxia-Ischemia, Brain — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypoxia-Ischemia, Brain with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07829887University of CalgaryCerebral Oximetry in Management of Post Cardiac Arrest | 2027-02 |
| NCT06985290Ipsita GoswamiDexmedetomidine Versus Morphine During Cooling Therapy in Neonates | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Some babies experience a lack of oxygen and blood flow around the time of birth. This can lead to a serious condition called hypoxic-ischemic encephalopathy (HIE), which can injure the brain and other organs, including the heart. To reduce brain injury, babies with HIE are treated with therapeutic hypothermia, a standard treatment in which the baby's body temperature is carefully lowered for several days. While cooling helps protect the brain, many babies with HIE still develop heart problems and low blood flow, which may worsen outcomes.
Doctors often use medications to support the heart and circulation in these babies, but there is no clear agreement on which medication works best or when it should be started. One commonly used medication is dobutamine, which helps the heart pump more effectively. Dobutamine is already used in newborn intensive care units when babies show signs of heart weakness, but it is usually started only after problems develop.
The PROTECT-HIE trial aims to find out whether it is possible and safe to start dobutamine early, before clear signs of heart failure appear, in newborns with HIE who are receiving therapeutic hypothermia. The idea is that early support of the heart may improve blood flow to vital organs, including the brain, and potentially reduce injury.
In this study, 40 newborns with HIE will take part at a single neonatal intensive care unit. Babies will be randomly assigned to one of two groups. One group will receive a low, preventative dose of dobutamine within the first four hours after cooling begins. The other group will receive a placebo (an inactive fluid that looks the same). Neither the families nor the medical team assessing outcomes will know which treatment the baby received.
The main goal of this study is to determine feasibility-that is, whether starting dobutamine early during cooling can be done reliably and safely in this setting. Researchers will also collect information on important health outcomes, such as signs of brain injury on MRI, seizures, need for additional heart medications, heart function on ultrasound, recovery of blood markers, urine output, length of hospital stay, and survival.
Because HIE is an emergency condition and treatment must start very soon after birth, parents will be approached for consent after the baby has been stabilized. This approach is commonly used in neonatal emergency research and has been approved in similar studies.
The results of this study will help determine whether a larger trial should be done in the future. Ultimately, this research aims to improve care and outcomes for babies affected by HIE by optimizing support for the heart during a critical period after birth.
Purpose
The purpose of this study is to evaluate the feasibility and safety of initiating prophylactic dobutamine infusion in newborns with hypoxic-ischemic encephalopathy (HIE) who are undergoing therapeutic hypothermia (TH). Infants with HIE frequently experience cardiovascular instability during the early postnatal period, which may negatively affect cerebral perfusion and overall outcomes. This study aims to determine whether early, preventive cardiovascular support can be reliably implemented and whether it may be associated with improved short-term clinical outcomes.
Hypothesis
The primary hypothesis is that initiating prophylactic dobutamine infusion within the first four hours of therapeutic hypothermia in newborns with HIE is feasible and safe.
The secondary hypothesis is that early dobutamine prophylaxis may be associated with improved short-term in-hospital outcomes, including reduced severity of brain injury, improved cardiac function, and reduced need for escalation of cardiovascular support.
Justification
HIE remains a major cause of neonatal mortality and long-term neurodevelopmental impairment despite the widespread use of therapeutic hypothermia. Up to 80% of infants with HIE experience some degree of cardiovascular compromise, particularly involving right ventricular dysfunction, which has been associated with worse neurological outcomes and increased mortality.
Although vasoactive medications are frequently used in this population, there is no standardized or evidence-based approach regarding the optimal agent or timing of initiation. Dobutamine is a commonly used inotropic agent in neonates, with a favorable physiological profile that enhances cardiac contractility without significant increases in heart rate or systemic vascular resistance. Preliminary observational data suggest that dobutamine improves cardiac output in infants with HIE undergoing hypothermia.
Currently, dobutamine is typically initiated only after cardiovascular compromise becomes clinically apparent. A prophylactic approach, initiated early during therapeutic hypothermia, may help stabilize cardiac function, optimize systemic and cerebral perfusion, and potentially reduce secondary brain injury. Before a definitive efficacy trial can be conducted, it is necessary to establish the feasibility, safety, and protocol adherence of such an intervention. This pilot randomized controlled trial is designed to address that critical knowledge gap.
Objectives
Primary Objective
To determine the feasibility of initiating prophylactic dobutamine infusion within the first four hours of starting therapeutic hypothermia in newborns with HIE.
Secondary Objectives
To explore whether prophylactic dobutamine is associated with improved short-term clinical outcomes, including:
Presence and severity of brain injury on MRI Mortality Seizure activity (clinical or electrographic) Need for escalation of inotropic or vasoactive support Echocardiographic measures of cardiac function and pulmonary hemodynamics Time to normalization of lactate Duration of inhaled nitric oxide therapy, if required Urine output at 24, 48, and 72 hours Length of hospital stay until discharge or death Research Method / Procedures
This study is a single-center, double-blinded, randomized controlled feasibility trial conducted in a tertiary neonatal intensive care unit.
Eligible participants are newborns diagnosed with hypoxic-ischemic encephalopathy who are receiving therapeutic hypothermia. Infants will be excluded if they have congenital anomalies, contraindications to dobutamine, significant arrhythmias, or if they have already been started on inotropic support prior to randomization.
Participants will be randomized in a 1:1 ratio to either:
Intervention group: Prophylactic dobutamine infusion at 10 mcg/kg/min Control group: Placebo infusion (dextrose 5%) identical in appearance and administration Randomization will be computer-generated, with allocation concealment ensured through a secure REDCap system. The study will be double-blinded; parents, clinical staff, outcome assessors, and data analysts will remain unaware of group assignment until completion of the final analysis.
The assigned infusion (dobutamine or placebo) will be initiated within four hours of starting therapeutic hypothermia and continued until clinical improvement, escalation of cardiovascular support, or weaning at the discretion of the clinical team.
All participants will undergo standardized targeted neonatal echocardiography at two predefined time points during the first 48 hours. Clinical data will be collected throughout hospitalization, including laboratory results, imaging findings, medication use, adverse events, and outcomes.
Due to the emergency nature of HIE and the need for timely initiation of treatment, a deferred consent model will be used. Parents of surviving infants will be approached for written consent as soon as feasible after stabilization and prior to discharge. For infants who die before consent can be obtained, a waiver of consent will be requested for collection of minimal anonymized data.
Plan for Data Analysis
The primary analysis will focus on feasibility outcomes, including:
Proportion of eligible infants successfully receiving the intervention within four hours of initiating therapeutic hypothermia Protocol adherence rate The study will be considered feasible if more than 60% of eligible infants are recruited and more than 75% of randomized infants receive the assigned intervention without major protocol deviations.
Secondary clinical outcomes will be analyzed descriptively, as this pilot study is not powered to detect definitive efficacy differences. Continuous variables will be summarized using means, standard deviations, medians, and interquartile ranges as appropriate. Categorical variables will be reported as frequencies and percentages.
Comparisons between groups will be conducted using:
Student's t-test or Mann-Whitney U test for continuous variables Chi-square test for categorical variables All analyses will follow the intention-to-treat principle. Statistical significance will be defined as a two-sided p-value \<0.05. Analyses will be performed using IBM SPSS and SAS statistical software after database lock and unblinding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
known of dobutamine
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
If randomized to the prophylaxis/dobutamine arm, dobutamine will be administered at a dose of 10 mcg/kg/min via intravenous access within 4 hours of initiating TH. As a part of standard care for HIE, a central umbilical venous access is routinely acquired whenever possible. We will use the dobutamine concentration of 2000 mcg/ml. The infusion will be prepared in dextrose 5% solution in 50 mL bags. Dobutamine monograph is attached to the protocol as well (Appendix F). The infusion will be continued until either weaned by the clinical team, escalation of inotropic support, or improvement of clinical situation to allow weaning of dobutamine.
Drug: Dobutamine · Diagnostic Test: TnECHO
Infants randomized to the placebo arm will receive an inert preparation containing no active pharmacologic agent. The placebo will be identical in appearance, volume, and method of administration to the active intervention and will be administered according to the same dosing schedule and duration. We will use dextrose 5% (as placebo), which will be started within 4 hours of initiating TH. The infusion will be continued until either weaned by the clinical team, escalation of inotropic support, or improvement of clinical situation to allow weaning of dobutamine.
Diagnostic Test: TnECHO
If randomized to the prophylaxis/dobutamine arm, dobutamine will be administered at a dose of 10 mcg/kg/min via intravenous access within 4 hours of initiating TH. As a part of standard care for HIE, a central umbilical venous access is routinely acquired whenever possible. We will use the dobutamine concentration of 2000 mcg/ml. The infusion will be prepared in dextrose 5% solution in 50 mL bags. Dobutamine monograph is attached to the protocol as well (Appendix F). The infusion will be continued until either weaned by the clinical team, escalation of inotropic support, or improvement of clinical situation to allow weaning of dobutamine.
In both groups, 2 TnECHOs will be performed. TnECHO T1 will be performed within the 24 hours of randomization, and TnECHO T2 will be performed within 24-48 hours after TnECHO T1. All echocardiographic assessments are done by physicians trained in TnECHO or by pediatric cardiology team. Echocardiographic assessment will be performed as per the American Society or Echocardiography guidelines(63-66). Details of the standardised echo views and measurements are outlined in Appendix B.
Feasibility/Safety
Proportion of eligible infants receiving the intervention (or placebo) within 4 hours of initiating TH
Time frame: At 24 hours of age
Brain injury
Brain injury on MRI (normal/abnormal)
Time frame: through study completion, an average of 1 month
Severity and type of brain injury
Severity and type of brain injury on head MRI \[as per reference # 72 in the uploaded protocol, Mohammad K, et al. Consensus Approach for Standardization of the Timin\]
Time frame: through study completion, an average of 1 month
Mortality
Death (yes/no)
Time frame: through study completion, an average of 1 month
Seizure activity
Presence of seizure activity either clinically or on EEG (yes/no)
Time frame: through study completion, an average of 1 month
Need for escalation the inotropic support
Need for escalation the inotropic support (beyond the above-mentioned infusions) (yes/no)
Time frame: through study completion, an average of 1 month
TAPSE in mm
Echocardiographic parameter
Time frame: through study completion, an average of 1 month
RV FAC in %
Echocardiographic parameter
Time frame: through study completion, an average of 1 month
LV EF in %
Echocardiographic parameter
Time frame: through study completion, an average of 1 month
Time to normalizing lactate in hours
Time to normalizing lactate reported in hours (the cutoff for normal lactate is 3 as per local laboratory values)
Time frame: through study completion, an average of 1 month
Duration of inhaled nitric oxide in hours
Duration of inhaled nitric oxide if needed reported in hours from the time of initiation to time of discontinuation
Time frame: through study completion, an average of 1 month
Urine output in cc/k/hour
Urine output reported at 24, 48, and 72 hours reported in cc/k/hour
Time frame: through study completion, an average of 1 month
Length of hospital stay in days
Length of stay in hospital in days defined from the date of birth till the date of discharge/death
Time frame: through study completion, an average of 1 month
Plan to share: No — IPD will not be shared to protect patient confidentiality. However, this could be re-considered if ethics approval is obtained from the requesting researcher and also the source ethics board.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Apr 2029, 30 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dobutamine